Pol Boudes, M.D.

Pol Boudes, M.D., is the Chief Medical Officer at Rectify Pharma. Prior to joining Rectify, he served as Chief Medical Officer of Galectin Therapeutics, where he advanced belapectin to Phase 3 development for the treatment of liver cirrhosis. He previously served as Chief Medical Officer at CymaBay Therapeutics, where he led all pipeline programs, including seladelpar for the treatment of primary biliary cholangitis, and supported the completion of multiple financing rounds. Prior to CymaBay, he served as Chief Medical Officer of Amicus Therapeutics, where he pioneered the development of chaperone therapies for the treatment of lysosomal storage disorders. Earlier in his career, he held senior international roles at Bayer, Wyeth-Ayerst Research and Roche. Pol is a board member of Protalix Biotherapeutics. Pol brings more than thirty years of R&D, clinical, medical affairs, and biotech leadership experience and is a board-certified physician in endocrinology and metabolic diseases with specialization in internal medicine and geriatric diseases. He received his M.D. from the University of Marseille, France